NEKTAR THERAPEUTICS

NKTR
Delayed Quote. Delayed  - 10/28 04:00:00 pm
15.91USD -3.46%
Prev.16.4800
Open16.1100
High16.4900
Low15.8000
Volume1 314 648
Latest news
13h ago
10/02
08/12
08/07
Chart NEKTAR THERAPEUTICS
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishNeutral
Resistance18,420,326,9
Spread/Res.-14%-22%-41%
Spread/Supp.-2,3%-2,3%-2,2%
Support16,316,316,3
Financials
Sales 2020 147 M - -
Net income 2020 -502 M - -
Net cash 2020 170 M - -
P/E ratio 2020 -5,63x
Yield 2020 -
Capitalization 2 846 M 2 846 M -
EV / Sales 2020 18,2x
EV / Sales 2021 15,8x
Nbr of Employees 723
Free-Float 99,2%
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties...

>> Read more
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2020-11-04 Earnings Release
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 30,83 $
Last Close Price 15,91 $
Spread / Highest target 403%
Spread / Average Target 93,8%
Spread / Lowest Target 6,85%